SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results
Rhea-AI Summary
SIGA (Nasdaq: SIGA) will host a business update webcast and conference call on Thursday, November 6, 2025 at 4:30 P.M. ET following release of third-quarter 2025 results.
Management participants include Diem Nguyen, CEO, and Daniel Luckshire, CFO. The live webcast will be available in the Investor Relations section of the company website and by dialing the domestic or international conference numbers. A replay will be available for two weeks with Conference ID 1141989. Attendees are asked to log in 5–10 minutes before the start time.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, SIGA gained 2.21%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 6, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
A live webcast of the call will also be available on the Company's website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.
Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1141989. The archived webcast will be available in the Investor Relations section of the Company's website.
About SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit www.siga.com.
Contact:
Suzanne Harnett
sharnett@siga.com
FAQ
When will SIGA (SIGA) host its Q3 2025 business update call?
Who will speak on SIGA's November 6, 2025 webcast?
How can investors access the live SIGA conference call on November 6, 2025?
Will there be a replay of SIGA's November 6, 2025 business update call?
Where is SIGA's webcast archived after the November 6, 2025 call?
When should I log in to SIGA's November 6, 2025 webcast?
